Senti Biosciences Holdings, Inc.
SNTI Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.19
KIRA · Stoqly’s AI analyst, in plain words
- Senti Biosciences Holdings, Inc. had $0.0M of revenue in fiscal 2025.
- Its operating margin was −312,631.8%: of every 100 in sales, about −312,632 is left after running the business.
- Senti Biosciences Holdings, Inc. lost $61.4M in fiscal 2025.
- Free cash flow was −$43.6M in fiscal 2025, −198,363.6% of revenue.
Market cap
$5.8M
P/E
—
Revenue
$0.0M
Net income
−$61.4M
Free cash flow
−$43.6M
Operating margin
−312,631.8%
Senti Biosciences Holdings, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−279,263.6%
No. It lost money last year.
Does profit turn into cash?
−198,363.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Senti Biosciences Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Senti Biosciences Holdings, Inc.
- CIK
- 0001854270
Senti Biosciences Holdings, Inc. · SNTI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.8M | $4.3M | $2.6M | $0.0M | $0.0M |
| Revenue growth | — | 55.2% | −40.2% | −100.0% | — |
| Operating margin | −1,464.9% | −1,448.5% | −3,620.7% | — | −312,631.8% |
| Net income | −$55.3M | −$58.2M | −$71.1M | −$52.8M | −$61.4M |
| Net margin | −2,003.6% | −1,358.1% | −2,774.6% | — | −279,263.6% |
| Diluted EPS | −$19.00 | −$2.23 | −$16.01 | −$12.03 | −$2.73 |
| Cash | |||||
| Cash from operations | −$34.6M | −$34.9M | −$52.4M | −$41.4M | −$43.4M |
| Capital expenditure | $5.5M | $41.4M | $12.0M | $0.0M | $0.2M |
| Free cash flow | −$40.2M | −$76.3M | −$64.4M | −$41.4M | −$43.6M |
| FCF margin | −1,455.2% | −1,779.5% | −2,515.9% | — | −198,363.6% |
| Share count change | — | 796.6% | −83.0% | 3.6% | 389.2% |
| Debt and strength | |||||
| Cash and short-term investments | $56.0M | $98.6M | $35.9M | $48.3M | $16.4M |
| Shareholders' equity | −$111M | $127M | $66.9M | $25.6M | $5.6M |
| Current ratio | 4.1x | 5.7x | 5.6x | 4.5x | 1.7x |
| Returns and quality | |||||
| Return on equity | — | −736.6% | −73.2% | −114.1% | −393.4% |
| Return on tangible equity | — | −45.7% | −106.2% | −215.6% | −1,099.3% |
| Piotroski F-score | — | 3 | 2 | 2 | 2 |
| Altman Z'' | −6.8 | 0.1 | −7.3 | −10.4 | −30.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Senti Biosciences Holdings, Inc. · SNTI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.19 a share, the company is worth $5.8M.
Source: SEC EDGAR XBRL filings (CIK 0001854270). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.